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ABSTRACT: NADH mimics (mNADHs) have been shown to accelerate and orthogonally activate ene reductase-catalyzed reac-
tions. However, existing regeneration methods of NAD(P)H fail for mNADHs. Catalysis with artificial metalloenzymes based on 
streptavidin (Sav) variants and a biotinylated iridium cofactor enable the mNADHs regeneration with formate. This regeneration 
can be coupled with ene reductase-catalyzed asymmetric reduction of α,β-unsaturated compounds, due to the protective compart-
mentalization of the organometallic cofactor.  With 10 mol% mNAD+, a preparative scale reaction (> 100 mg) gave full conversion 
with 98 % e.e, where TTNs reached 2000 with respect to the Ir cofactor under ambient atmosphere in aqueous medium.
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The increasing industrial use of biocatalytic processes can 
by-and-large be traced back to the high chemo-, regio-, and 
enantioselectivity of engineered enzymes.1-7 These features 
enable low priced products thanks to high space time yields, 
reduced separation expenditures and waste formation. Oxi-
doreductases are firmly established as valuable tools for syn-
thetic chemistry purposes. However, more than 400 enzymatic 
redox reactions require relatively costly pyridine nucleotide 
cofactors NAD(P)H as redox equivalents, typically in combi-
nation with an enzymatic recycling system.8-10 
Various synthetic NAD(P)H mimics (mNADHs) have been 
synthesized for various purposes including: i) mechanistic 
probes,11-13 ii) a decrease in the relatively expensive operation-
al costs of NAD(P)H-dependent enzymes,14 iii) the enhance-
ment of the catalytic activity of selected NADH-dependent 
enzymes and iv) orthogonality against NADH as a limited 
number of enzymes accept mNAD(H) as cofactor (Scheme 
1).14-20 Simple mNADHs 1-5 (Scheme 1) might however suffer 
from various disadvantages, foremost the limited number of 
enzymes that accept them as redox equivalents. Further poten-
tial drawbacks include low solubility of the reduced form of 
the mimic and reduced chemical stability, if the mimics are 
electronically very different from natural NAD(P)H. 
For in situ NAD(P)H regeneration, enzymes, such as alco-
hol dehydrogenases, glucose dehydrogenases and phosphite 
dehydrogenase, have been widely utilized.21,22 However, these 
enzymatic methods cannot be applied to mNAD+s, as these do 
not accept mNAD+ as a substrate (see iv) above). Recently an 
in situ catalytic reduction of mNAD+ by a rhodium complex 
was reported, albeit at the cost of a low TTN.19 To date, only 
few studies report the in situ regeneration of mNADHs which, 
has hampered their widespread use as redox mediators.14,16,23-27  
Regeneration challenges typically include: i) deactivation of 
the enzymatic partners and/or organometallic regeneration 
catalyst as well as ii) low productivity, selectivity and initial 
activity.28-33 The very limited success in mNADH regeneration 
severely hampers their widespread use and application.  
In the past decade, artificial metalloenzymes (AMEs) have 
attracted attention as an alternative to both homogeneous cata-
lysts and enzymes.34-43 In this context we have shown that 
artificial transfer hydrogenases (ATHases) based on an abiotic 
biotinylated Ir-pianostool cofactor, IrC (Scheme 1c) and strep-
tavidin variants, provide an attractive solution to the incompat-
ibility of synthetic transition metal catalysts and enzymes.44-51 
Cascade reactions of ATHases with a range of different en-
zymes, namely a flavin dependent monooxygenase, heme de-
pendent enzymes (catalase and peroxidase), a flavin dependent 
amine oxidase and amino acid oxidases were realized.52 Since 
ATHases can reduce NAD(P)+,52,53 we set out to explore the 
versatility of ATHases towards the regeneration of mNAD+s.   
As an mNADH-accepting enzyme, the ene reductase (ER) 
of the Old Yellow Enzyme family from Thermus scotuductus 
(TsOYE) was selected.14,54 Compared to the use of NAD(P)H, 
similar or even higher initial rates and conversions have been 
reported for reactions involving stoichiometric amounts of the 
mimic 1 in the presence of TsOYE.14,19 ATHases were gener-
ated by employing a 1 : 2 ratio of the biotinylated cofactor and 
biotin binding sites.55 As a stoichiometric reducing agent, so-
dium formate was selected (Scheme 1a). To identify an effi-
cient regeneration system for the reduction of N-ethyl-2-
methylmaleimide 6 (Scheme 2) with TsOYE, five different 
NAD+ mimics 1-5 (Scheme 1b) were screened in combination 
with the biotinylated Ir-cofactor IrC and a range of Sav vari-
ants. Previous studies with the ATHase have revealed that 
mutations at three close lying positions (i.e. S112, K121 and 
L124) have a significant impact on the catalysis outcome 
(Scheme 1c).56 
  
Scheme 1. (a) Catalytic reduction of Michael acceptors by 
ene reductase (ER) and concurrent catalytic cofactor re-
generation by IrCp* complexes. (b) Nicotinamide mimics 
1-5 (mNAD+) tested as cofactors in this study. (c) IrCp* 
complexes (IrA-C) and artificial transfer hydrogenase 
(IrC-Sav) tested for the reduction of mNAD+ 1-5. Inset: 
close-up view of the structure of IrC-Sav S112A variant 
(PDB ID: 3PK2). 
 
Although higher initial rates for mNAD+ 1 reduction were 
observed under acidic conditions (Table S2), the pH of the 
reaction was set to 7.0. This value constitutes a trade-off be-
tween the pH-dependence of the ATHase activity and the 
mNADH stability (Figure S1). Furthermore, a neutral pH pro-
vides sufficient hydrolytic stability of the maleimide 6 used as 
a model substrate.57,58 No significant influence of formate on 
the activity of TsOYE was observed (Figure S2). For the 
screening, both the biotinylated Ir-cofactor IrC as well as non-
biotinylated analogues IrA and IrB were included as catalysts 
(Scheme 1c). 
The fingerprint display summary (Scheme 2, Table S3) 
highlights the following features: a) mNADH 3 showed best 
performance in terms of enantioselectivity and GC-yield; b) 
four of the Sav variants with mNAD+ 3 provided higher GC-
yield and comparable activity to the protein-free cofactor IrC 
or its non-biotinylated analogues IrA and IrB; the best suited 
Sav variant is mutant S112K, providing over two-fold im-
provement compared to the protein-free Ir complexes.; c) 
while it has been previously shown that stoichiometric 
amounts of mNADH 1 combined with TsOYE leads to the 
best GC-yield,14 the mimic mNADH 3 proved most suitable 
(both in terms of e.e. and GC-yield) for the cascade including 
the Ir-based ATHase regeneration system (Figure S3)9,59,60  
and d) the nature of the mNADH plays a critical role in deter-
mining the e.e. of the reduction product 7.  We assume that the 
last point is due to the relative rates of reduction of mNAD+ 1-
5 vs. substrate 6 by the ATHase (vide infra).14  
 
Scheme 2. Fingerprint display of the GC-yield and e.e. for 
N-ethyl-2-methylmaleimide 6 reduction by TsOYE / 
mNADHs 1-5 and IrCp* / HCOOH based regeneration 
system. 10 µM catalyst (IrCp*), 0.5 mg/ml (3 µM) TsOYE, 
1 mM mNAD+, 10 mM N-ethyl-2-methylmaleimide 6, and 
2.0 M HCOONa in 0.6 M MOPS (pH 7.0); experiments 
were performed at 30 ºC for 4 h on a 400 µ l scale. GC-
yield and enantiomeric excess (e.e.) were determined by 
GC with benzyl alcohol as internal standard; GC-yields 
are based on product formation. 
 
In order to evaluate the inactivation of the Ir-based regener-
ation catalyst in the presence of TsOYE, the initial rate of 
mNAD+ 3 reduction was determined spectrophotometrically 
(Figure S4). The initial rate for the protein-free cofactor IrC is 
about 1.6 fold faster than for the best ATHase IrC-Sav S112K. 
 However, in the presence of the TsOYE, the relative activity is 
reversed: the protein-free cofactor IrC looses over 80% of its 
initial activity. In stark contrast, it maintains over 80% of its 
activity when incorporated into Sav S112K (Figure 1). The 
TsOYE maintains its activity in the presence of either IrC or 
IrC-Sav112K (Figure S5). 
 
 
Figure 1. Initial rates of mNAD+ 3 reduction catalyzed by (a) IrA, 
(b) IrB, (c) IrC, and (d) IrC-Sav S112K in the absence (solid line) 
and in the presence of TsOYE (dashed line) monitored by UV-vis 
absorption at 378 nm. 10 µM Ir-catalyst, 0.5 mg/ml (3 µM) 
TsOYE, 1 mM mNAD+ 3, and 2.0 M HCOONa in 0.6 M MOPS 
(pH 7.0); experiments were performed at 25 ºC. 
 
After identifying the combination of mNAD+ 3, IrC and Sav 
S112K as the most efficient artificial cofactor regeneration 
system, it was compared with the established regeneration 
method for reducing equivalents comprised of NAD(P)+, GDH 
and glucose (1.2 mg of GDH per ml). TsOYE mediated reduc-
tion coupled to the mNAD+ 3–ATHase system (10 µM, 1.2 mg 
of Sav per ml) gave higher GC-yield than with the NAD+–
GDH system at the cost of a slightly eroded enantioselectivity 
(Table 1, entries 1, 10). In combination with the NADP+–GDH 
system however, it outperformed both regeneration with 
mNAD+ 3–ATHase or with NAD+–GDH (Table 1, entry 2).14 
Regeneration of NADH or NADPH with the ATHase led to 
low GC-yield and nearly racemic product 7, suggesting that 
the N-ethyl-2-methylmaleimide 6 is a better substrate than 
NAD(P)+ for the ATHase (Table 1, entries 8, 9) leading to its 
direct (racemic) reduction by the {Ir–H}-moiety. 
To alleviate the erosive effect of the direct substrate (6) re-
duction on enantioselectivity of the cascade process, the load-
ing of mNAD+ 3 was set to 10 mol% - resulting in an e.e. of 
91-93% (see Table S4).  Gratifyingly, a set of alternative ERs 
(from Codexis) also readily accepted mimic 3 and were tested 
in the cascade reaction. Except for ERED-P1-E01, none of 
these compared favorably with TsOYE, (Table S5). 
Upon increasing the reaction time from four to seven hours, 
the initial loading of iridium could be reduced from the 0.1% 
to 0.05% without compromising the GC-yield (Table 1, entries 
10, 11). Slow addition of the substrate allowed to improve the 
e.e. further (up to 95-98% e.e.) by minimizing the background 
direct reduction of substrate 6 (Table 1, entries 11, 12). A pre-
parative scale reaction with N-ethyl-2-methylmaleimide 6 (1.0 
mmol) resulted in > 99% GC-yield (61% isolated yield) and 
98 % e.e. (Table 1, entry 13). 
Ketoisophorone 8 and 2-methylcyclohexenone 9 were re-
duced with moderate to good GC-yields when applied to the 
cascade (Table 1, entries 14-19). The lower enantioselectivity 
for the reduction of 8 reflects the trend observed in reactions 
with stoichiometric quantities of cofactor and is partly due to a 
known non-enzymatic racemization of the reduced product 
over time.14,61 
 
Table 1. Selected results for ERs using mNAD+ 3.a 
Entry ER IrC-S112K 
[mol%] 
(m)NAD(P)+ Substrate Time 
[h] 
e.e.   
[%] 
GC-yield 
[%] 
TTNIr TTNERh 
1 TsOYE GDHb NAD+ 
N OO
 
6 4 >99 (R) 65 195g 118 
2 TsOYE GDHb NADP+ 6 4 >99 (R) >99 >298g 181 
3 – 0.1 (IrA)c – 6 4 0 10 104 80 
4 – 0.1 (IrB)c – 6 4 2 (R) 5 5 4 
5 – 0.1 (IrC)c – 6 4 0 10 96 74 
6 – 0.1 – 6 4 3 (S) 14 136 105 
7 TsOYE 0.1 – 6 4 4 (S) 11 113 374 
8 TsOYE 0.1 NAD+ 6 4 4 (R) 12 117 390 
9 TsOYE 0.1 NADP+ 6 4 6 (R) 14 139 464 
10 TsOYE 0.1 mNAD+ 3 6 4 93 (R) 85 853 2843 
11 TsOYE 0.05 mNAD+ 3 6 7 91 (R) 87 1746 8730 
 12 TsOYE 0.05 mNAD+ 3 6 7d 95 (R) >99 >1980 >9900 
13 TsOYE 0.05 mNAD+ 3 6 7e 98 (R) >99 (61)f >1980 >9900 
14 TsOYE 0.05 mNAD+ 3 
O
O
 
8 8 86 (R) 30 556 2980 
15 TsOYE 0.05 mNAD+ 3 8 8d 85 (R) 23 467 2333 
16 TsOYE 0.05 mNAD+ 3 8 24 72 (R) 48 951 4756 
17 TsOYE 0.05 mNAD+ 3 
O
 
9 8 94 (R) 69 1385 6531 
18 TsOYE 0.05 mNAD+ 3 9 8d 94 (R) 69 1369 6457 
19 TsOYE 0.05 mNAD+ 3 9 12 82 (R) 83 1655 7799 
a Experiments were performed in 0.6 M MOPS, 2.0 M HCOONa (pH 7.0) at 30 °C and on a 400 µl scale (except entry 13); 10 mM (entries 
1-10) or 30 mM (entries 11-19) substrate, 3µM TsOYE, 1 mM (entry 10) or 3 mM (entries 11-19) mNAD+ 3 or 1 mM NAD(P)+ (entries 1, 
2, 8, 9). Average values for triplicate reactions are shown (except for entry 13); standard deviations were ≤ 1.4%. GC-yields were deter-
mined by GC with the following internal standards: benzyl alcohol for 6, cyclohexanol for ketoisophorone (8) and 2-methylcyclohexenone 
(9). Absolute configuration of 7 was tentatively assigned by comparison with N-phenyl-3-methylsuccinimide produced by TsOYE reduc-
tion.14 The absolute configuration of reduced 8 (levodione 10) by TsOYE reduction has been reported previously.14 Absolute configuration 
of reduced 9 (2-methylcyclohexanone 11) was tentatively assigned by optical rotation and comparison with literature data (see SI). b 1.2 
mg/ml of glucose dehydrogenase (GDH-105 from Codexis) and 100 mM glucose were used instead of ATHase IrC-Sav S112K and 
HCOONa.  c IrA, IrB, and IrC were used instead of IrC-S112K, respectively. d Half of the substrate was added at 0 h and after 1 h, respec-
tively. e Preparative scale reaction, 141 mg of 6 was added to the reaction mixture in portions every 10 min for 170 min. f isolated yield. g 
An accurate turnover number for the commercial GDH can not be calculated, since the enzyme is only semipurified according to the manu-
facturer. We calculated an upper limit based on 78% purity (determined by the Bradford assay)62 and a molecular weight of 28 kDa.63,64 
The reaction conditions have not been optimized for GDH. Alternative enzymes with potentially higher activity (e.g. Codexis CDX-901) 
are commercially available. h TTNs for TsOYE represent a lower limit based on protein content in the lyophilised preparation (20 wt%) as 
determined by the Bradford assay.
In summary, the first efficient regeneration system for 
NADH mimics has been developed and its applicability 
demonstrated in the combination with a range of ene reductas-
es. Further research will focus on the evaluation in concurrent 
reactions with other enzymes that accept mimics such as 
monooxygenases.18 To the best of our knowledge, the catalytic 
performance (i.e. TTN) of this Ir-based system for (m)NADH 
regeneration is the best reported for non-enzymatic regenera-
tion systems. Potential regeneration systems for mNAD+s will 
have to be scrutinized with respect to achievable turnover fre-
quency and total turnover number not only for the regenerat-
ing metal catalyst, but also for the mimic. 
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